USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Meiragtx UK II Limited

USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

7
Total patents granted
5
CPC technology areas
26.1
Avg claims per patent
+500%
5-year filing velocity

The verdict

Meiragtx holds 7 US patents across 5 technology areas, rank #36,492 of 50,000 tracked assignees.

#36,492
of 50,000 US assignees by volume
Top 14%
by Innovation Score (50.1/100)
26.1
avg claims per patent
+500%
filing velocity, last 5 yrs

Portfolio overview

Meiragtx UK II Limited has been granted 7 US utility patents between 2019 and 2025, placing Meiragtx UK II Limited at rank #36,492 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.1 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, Meiragtx UK II Limited is one of the more focused assignees in the PatentsView dataset. By volume, Meiragtx sits between Media Cart Holdings, Inc. (7 patents, rank #36,488) and Mercy Medical Research Institute (7 patents, rank #36,496) - the closest US assignees by grant volume. The composite Innovation Score of 50.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 1 in the 2015–2019 window, a +500% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Meiragtx UK II Limited's 26.1 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Meiragtx UK II Limited against peers pursuing similar technology classes.

Who files at Meiragtx's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Meiragtx holds 7 patents at rank #36,492, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Meiragtx

By rank, the assignees closest to #36,492 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Meiragtx's primary technology class.

Meiragtx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

50 Top 14% higher than 86% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 2019202220232025 1
USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
Meiragtx UK II Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 1 14.3%
2022 3 42.9%
2023 2 28.6%
2025 1 14.3%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating

Where it ranks

Overall rank by patents

#36,492

Across all tracked assignees

Innovation Score

50.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Meiragtx UK II Limited hold?
Meiragtx UK II Limited holds 7 US granted patents filed between 2019 and 2025, spanning 5 technology areas.
What is Meiragtx UK II Limited's Innovation Score?
Meiragtx UK II Limited has an Innovation Score of 50.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Meiragtx UK II Limited focus on?
Meiragtx UK II Limited's top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 7 patents. The company has filed patents in 5 CPC subclasses total.
Is Meiragtx UK II Limited's patent filing rate increasing or decreasing?
Meiragtx UK II Limited's recent filing velocity is +500% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Meiragtx UK II Limited's patents?
Meiragtx UK II Limited's patents average 26.1 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Meiragtx UK II Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Meiragtx's 7 grants land it in the top 14% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Meiragtx ranks #36,492 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.